897 related articles for article (PubMed ID: 29282151)
1. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Golan T; Milella M; Ackerstein A; Berger R
J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
[TBL] [Abstract][Full Text] [Related]
2. [Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer].
Bay JO; André T; Caux C; Evrard S; Gonçalves A; L'Allemain G; Magné N; Orbach D; Penel N; Rodrigues M; Thariat J; Thiery-Vuillemin A; Wislez M;
Bull Cancer; 2019 Jan; 106(1):12-23. PubMed ID: 30612698
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials in the era of personalized oncology.
Maitland ML; Schilsky RL
CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
[TBL] [Abstract][Full Text] [Related]
4. Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research.
Syme R; Carleton B; Leyens L; Richer E
Public Health Genomics; 2015; 18(6):372-80. PubMed ID: 26565702
[TBL] [Abstract][Full Text] [Related]
5. Trends and challenges in immuno-oncology trials.
Kiernan B
Drugs Today (Barc); 2016 Jul; 52(7):387-93. PubMed ID: 27540597
[TBL] [Abstract][Full Text] [Related]
6. [Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].
Vignot S; André T; Caux C; Bouleuc C; Evrard S; Gonçalves A; Lacroix M; Magné N; Massard C; Mazeron JJ; Orbach D; Rodrigues M; Thariat J; Wislez M; L'Allemain G; Bay JO
Bull Cancer; 2018 Jan; 105(1):6-14. PubMed ID: 29269176
[TBL] [Abstract][Full Text] [Related]
7. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Maio M; Coukos G; Ferrone S; Fox BA; Fridman WH; Garcia PL; Lahn M; Provendier O; Russo V; Rüttinger D; Shalabi A; Trajanoski Z; Viallet J; Wolchok JD; Ibrahim R
Cancer Immunol Immunother; 2019 Jan; 68(1):1-9. PubMed ID: 30564889
[TBL] [Abstract][Full Text] [Related]
8. Challenging Standard-of-Care Paradigms in the Precision Oncology Era.
Subbiah V; Kurzrock R
Trends Cancer; 2018 Feb; 4(2):101-109. PubMed ID: 29458960
[TBL] [Abstract][Full Text] [Related]
9. Personalized integrative oncology: targeted approaches for optimal outcomes: the 11th International Conference of the Society for Integrative Oncology.
Lee RT; Yang P; Greenlee H; Bauer-Wu S; Balneaves LG; Zick S
Integr Cancer Ther; 2015 Jan; 14(1):98-105. PubMed ID: 25505022
[TBL] [Abstract][Full Text] [Related]
10. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
11. Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
Martin SD; Coukos G; Holt RA; Nelson BH
Ann Oncol; 2015 Dec; 26(12):2367-74. PubMed ID: 26371284
[TBL] [Abstract][Full Text] [Related]
12. Immuno-Oncology in the Era of Personalized Medicine.
Gwin WR; Disis ML; Ruiz-Garcia E
Adv Exp Med Biol; 2019; 1168():117-129. PubMed ID: 31713168
[TBL] [Abstract][Full Text] [Related]
13. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
14. Landscape of early clinical trials for childhood and adolescence cancer in Spain.
Bautista F; Gallego S; Cañete A; Mora J; Diaz de Heredia C; Cruz O; Fernández JM; Rives S; Madero L; Castel V; Cela ME; Ramírez G; Sábado C; Acha T; Astigarraga I; Sastre A; Muñoz A; Guibelalde M; Moreno L
Clin Transl Oncol; 2016 Jul; 18(7):708-13. PubMed ID: 26489424
[TBL] [Abstract][Full Text] [Related]
15. The hubris and humility of cancer pharmacology in the post immuno-oncology era.
Lazo JS
Pharmacol Res Perspect; 2019 Dec; 7(6):e00527. PubMed ID: 31624635
[TBL] [Abstract][Full Text] [Related]
16. Translating genomic discoveries to the clinic in pediatric oncology.
Glade Bender J; Verma A; Schiffman JD
Curr Opin Pediatr; 2015 Feb; 27(1):34-43. PubMed ID: 25502895
[TBL] [Abstract][Full Text] [Related]
17. The future of oncology therapeutics.
Mansinho A; Boni V; de Miguel M; Calvo E
Expert Rev Anticancer Ther; 2017 Jul; 17(7):563-565. PubMed ID: 28504011
[No Abstract] [Full Text] [Related]
18. Clinical cancer research: the past, present and the future.
DeVita VT; Eggermont AM; Hellman S; Kerr DJ
Nat Rev Clin Oncol; 2014 Nov; 11(11):663-9. PubMed ID: 25245981
[TBL] [Abstract][Full Text] [Related]
19. Immuno-oncology for surgeons.
Lee SL; Al-Shamkhani A; Mirnezami A
Br J Surg; 2019 Sep; 106(10):1273-1282. PubMed ID: 31318438
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.
Siu LL; Ivy SP; Dixon EL; Gravell AE; Reeves SA; Rosner GL
Clin Cancer Res; 2017 Sep; 23(17):4950-4958. PubMed ID: 28864723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
